Holen Sie sich die Stockscreener-App
8.27
5.92%
-0.52
Handel nachbörslich:
8.27
Schlusskurs vom Vortag:
$8.79
Offen:
$8.76
24-Stunden-Volumen:
461.29K
Relative Volume:
1.04
Marktkapitalisierung:
$457.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.2412
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+6.64%
1M Leistung:
+11.61%
6M Leistung:
-48.25%
1J Leistung:
-70.83%
1-Tages-Spanne:
$8.26
$8.80
1-Wochen-Bereich:
$7.70
$8.97
52-Wochen-Spanne:
$6.85
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.27 | 457.66M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Invesco Ltd. Buys 1,395 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for CGEM - Defense World
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know - Yahoo Finance
Cullinan Therapeutics to begin US trial of CLN-978 to treat Sjögren’s disease - Yahoo Finance
Barclays PLC Has $2.99 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Reduced by Legal & General Group Plc - Defense World
Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease - marketscreener.com
Cullinan Therapeutics (CGEM) Begins Study of CLN-978 for Sjogren - GuruFocus
Cullinan Therapeutics to Initiate Study of CLN-978, a - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Brokerages - Defense World
SEC Form DEF 14A filed by Cullinan Therapeutics Inc. - Quantisnow
Shareholders Can't Ignore US$502k Of Sales By Cullinan Therapeutics Insiders - simplywall.st
JPMorgan Chase & Co. Buys 169,104 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) to Present Promising Lung Cancer St - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phas - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - The Manila Times
Cullinan Therapeutics to Present Positive REZILIENT1 Study Results of Zipalertinib for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Why Acquire Shares Of Cullinan Therapeutics Inc (CGEM)? - Marketing Sentinel
Geode Capital Management LLC Acquires 6,220 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Federated Hermes Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Reiterates “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial - Yahoo
EMA greenlights Cullinan’s arthritis drug trial in Europe By Investing.com - Investing.com South Africa
Cullinan gets EU nod to begin testing CLN-978 in rheumatoid arthritis - Seeking Alpha
Cullinan Therapeutics Receives Approval from European Medicines - GuruFocus
Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial | CGEM Stock News - GuruFocus
EMA greenlights Cullinan’s arthritis drug trial in Europe - Investing.com
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewswire
Vanguard Group Inc. Reduces Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Wellington Management Group LLP Has $1.62 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 6,800 Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by American Century Companies Inc. - Defense World
Corebridge Financial Inc. Sells 1,941 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data - Seeking Alpha
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):